Skip to main content
Premium Trial:

Request an Annual Quote

Drug & Market Development Productions, Agilent

Premium

Drug & Market Development Productions has released a new market report entitled Commercial Opportunities in RNA Interference — The Emerging Revolution.

The report, said D&MD, includes assessments of the projected market impact of RNAi through 2008, the commercial opportunities for using related technologies, those in the industry, the patenting of RNAi, and the technical aspects of the technology.

The chapters of the report can be ordered separately for prices ranging from $250 to $1,000, and the entire report can be purchased for $4,950. Details about the report can be found at http://www.drugand market.com/9126.


Agilent said this week that it has introduced the Agilent Total, a new RNA isolation kit it claims is capable of removing 1,000 times more genomic DNA than competing products.

According to Agilent, the kit does not use DNase enzyme, which can compromise the quality of RNA, and it has a pre-filtration column that removes genomic DNA contamination to less than one femtogram per one nanogram of isolated RNA in selected tissues.

Details about the Agilent Total, which is to be made available on Nov. 1, can be found at www.agilent.com/chem/dna.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.